¶ bacteria
¶ Definition
Single-celled prokaryotic microorganisms lacking a membrane-bound nucleus, classified structurally as Gram-positive (thick peptidoglycan wall) or Gram-negative (outer LPS membrane), comprising both beneficial commensal species that synthesize vitamins and metabolites essential for host health, and pathogenic species that trigger innate immune responses through pattern recognition receptor activation. Bacterial composition, diversity, and metabolic output profoundly influence immune tolerance, metabolic function, and neurological health through the microbiome-gut-brain axis, making bacterial balance a foundational pillar of clinical PNI.
¶ Picture It
Think of bacteria as the workforce in a massive city—some are sanitation workers keeping streets clean (Faecalibacterium producing butyrate to maintain gut barrier), some are food manufacturers producing essential supplies (Bifidobacteria synthesizing B vitamins), and some are construction crews maintaining infrastructure (Akkermansia strengthening the mucus layer). The city has roughly 40 trillion workers, outnumbering the city's actual residents (your human cells). When the workforce is diverse and balanced, the city thrives—waste is processed efficiently, nutrients are manufactured on-site, and security systems (immune cells) remain calm because they recognize these workers as "locals."
But when antibiotics act like a natural disaster, they don't discriminate—they wipe out entire neighborhoods of workers. The construction crews disappear, leaving buildings (gut barrier) to deteriorate. The food manufacturers vanish, creating vitamin shortages. And in the empty neighborhoods, gangs move in—pathogenic bacteria like E. coli and Klebsiella that the immune system doesn't recognize as locals. These troublemakers wear different uniforms: Gram-negative gangs have leather jackets studded with LPS (the molecular equivalent of gang colors), which trigger TLR4 alarm systems in immune cells. Gram-positive gangs wear thick peptidoglycan vests recognized by TLR2. When too many troublemakers accumulate, the immune police go on high alert, patrolling aggressively even in safe neighborhoods—this is chronic low-grade inflammation. The key to city health isn't eliminating all bacteria (that's impossible), but maintaining the right balance of workers to troublemakers.
¶ Mechanism
Bacterial recognition cascade:
-
Pattern recognition: Bacterial PAMPs (pathogen-associated molecular patterns) are detected by host PRRs (pattern recognition receptors)
- Gram-negative LPS (lipid-A moiety) → TLR4 on macrophages, dendritic cells, epithelial cells
- Gram-positive peptidoglycan + lipoteichoic acid → TLR2/TLR6 heterodimer
- Flagellin (bacterial flagella protein) → TLR5 on intestinal epithelium
- Unmethylated CpG DNA → TLR9 in endosomes
- Peptidoglycan fragments → NOD1/NOD2 (cytoplasmic NLRs)
-
TLR4-LPS signaling (Gram-negative inflammation):
- LPS binds LBP (LPS-binding protein) in plasma → LPS-LBP complex delivered to CD14 on macrophage → transfers to MD-2/TLR4 complex
- TLR4 activation → MyD88-dependent pathway → IRAK1/4 → TRAF6 → IKK complex → IκB phosphorylation and degradation → NF-κB nuclear translocation
- NF-κB transcription → IL-1β, IL-6, TNF-α, IL-8 (pro-inflammatory cytokines)
- TRIF-dependent pathway (late phase) → IRF3 → Type I interferons (IFN-α/β)
- Threshold: >5 pg/mL LPS in plasma = endotoxemia; >10 pg/mL = systemic inflammatory activation
-
Beneficial bacterial metabolite production:
- SCFA synthesis: Fiber fermentation by Faecalibacterium prausnitzii, Roseburia, Eubacterium → butyrate (4 carbons), propionate (3 carbons), acetate (2 carbons)
- Butyrate → colonocyte energy source (70% of colonocyte ATP), GPR109A activation → IL-10 and Treg induction, HDAC inhibition → Foxp3 expression in naive T cells
- Propionate → GPR41/43 activation → leptin release from adipocytes, gluconeogenesis suppression in liver
- Acetate → crosses blood-brain barrier, hypothalamic GPR43 activation → appetite regulation
-
Vitamin synthesis by commensal bacteria:
- Vitamin K2 (menaquinones): Bacteroides, Bacillus subtilis, E. coli (menaquinone-4 through menaquinone-13)
- B-complex: Bifidobacterium (B1, B2, B9, B12), Lactobacillus (B2, B3, B9), Bacteroides (B5, B7)
- Antibiotic disruption → 30-50% reduction in circulating B vitamins within 7 days
-
Barrier regulation:
- Commensal bacteria → TLR2 signaling → ZO-1 and occludin upregulation in tight junctions
- Akkermansia muciniphila → mucin degradation → mucus layer homeostasis (regulated turnover prevents pathogen adhesion)
- Pathogenic bacteria (Enterobacteriaceae) → zonulin release → tight junction disassembly → increased permeability
-
Immune education in GALT:
- Dendritic cells sample bacteria via M cells in Peyer's patches
- Commensal bacteria (Bacteroides fragilis) → PSA (polysaccharide A) → TLR2 on DCs → IL-10 secretion → naive CD4+ T cell → Foxp3+ Treg differentiation
- Pathogenic bacteria → IL-12/IL-23 from DCs → Th1/Th17 differentiation
- Segmented filamentous bacteria (SFB) → direct epithelial contact → serum amyloid A → Th17 induction (dual role: protective in gut, pathogenic systemically)
¶ Clinical Significance
In cPNI practice, bacterial composition is the foundation of immune tolerance and metabolic health. Dysbiosis—characterized by reduced diversity (<500 species vs. healthy 1000+), loss of SCFA producers (Faecalibacterium <5% of microbiota), and pathogen overgrowth (Enterobacteriaceae >10%)—drives the chronic low-grade inflammation underlying metabolic syndrome, autoimmunity, and neuropsychiatric disorders. This aligns with Metamodel 5 (chronic low-grade inflammation) and Metamodel 3 (selfish immune system): when the immune system loses tolerance to commensal bacteria, it enters a hypervigilant state, diverting energy from tissue repair and growth to continuous pathogen surveillance.
Key clinical applications:
Assessment priorities:
- Fecal calprotectin (>50 μg/g = intestinal inflammation, often bacterial-driven)
- SCFA analysis (total SCFA <60 mmol/kg or butyrate <15 mmol/kg = dysbiosis)
- Microbial diversity indices (Shannon index
.0 = low diversity associated with metabolic disease) - LPS/endotoxin levels (>5 pg/mL = endotoxemia from bacterial translocation)
- Secretory IgA (stool sIgA <500 μg/g = impaired mucosal immunity, allows pathogen overgrowth)
Intervention strategy:
-
Antibiotic stewardship: Every antibiotic course depletes Bifidobacteria and Lactobacilli for 6+ months, increases Enterobacteriaceae, and reduces vitamin K2/B-complex synthesis. If antibiotics are necessary, co-administer S. boulardii (500 mg BID) and follow with targeted probiotic restoration for 3-6 months.
-
Prebiotic fiber: 25-35g daily from diverse sources (inulin, resistant starch, pectin) feeds SCFA producers. Clinical threshold: butyrate production requires ≥20g fermentable fiber daily.
-
Probiotic selection:
- Immune tolerance: Lactobacillus rhamnosus GG (1×10¹⁰ CFU/day) → IL-10 induction
- Barrier repair: Akkermansia muciniphila (2.5×10¹⁰ CFU/day pasteurized form) → mucus layer restoration
- Anti-inflammatory: Faecalibacterium prausnitzii A2-165 → butyrate production
-
Pathogen suppression: Antimicrobial botanicals (berberine, oregano oil, neem) when SIBO or pathogenic overgrowth confirmed, followed by immediate ecosystem restoration (not prolonged antimicrobial use).
Evolutionary mismatch context: Modern humans evolved in high-bacterial-diversity environments with constant microbial exposures from soil, untreated water, and fermented foods. The hygiene hypothesis explains how reduced bacterial diversity in Westernized environments (antibiotic overuse, C-sections without vaginal microbiome seeding, formula feeding, sterilized food supply) creates immune systems with impaired tolerance education—manifesting as allergy, autoimmunity, and inflammatory bowel disease. The PARSIFAL and PASTURE studies demonstrated 50% lower asthma/atopy rates in farm-exposed children with higher bacterial diversity.
¶ Key Facts
- Human microbiome contains ~40 trillion bacteria (1.3:1 bacteria-to-human-cell ratio), concentrated in colon at 10¹⁰-10¹² CFU/g (highest bacterial density in body)
- Healthy microbiome comprises 1000+ species; dysbiosis defined as <500 species or <150 functional genes
- Gram-negative bacteria (Enterobacteriaceae, Bacteroides) have outer LPS membrane triggering TLR4 → NF-κB → IL-6/TNF-α within 30 minutes; Gram-positive (Firmicutes, Actinobacteria) have peptidoglycan wall activating TLR2
- SCFA-producing bacteria (Faecalibacterium prausnitzii, Roseburia, Eubacterium) reduced to <5% of microbiota in IBD, obesity, T2D (normal 10-15%)
- Beneficial bacteria synthesize 50% of daily vitamin K2 requirement and 30% of B-complex needs; antibiotics cause measurable vitamin deficiency within 1 week
- Bacterial diversity inversely correlates with metabolic disease: each 10% reduction in Shannon diversity index = 15% increased diabetes risk
- Pathogenic bacteria (E. coli, Klebsiella, Enterobacter, Proteus) comprise <1% of healthy microbiota but expand to >10% in dysbiosis, producing LPS and urease that alkalinize gut pH
- Bacterial translocation occurs when gut permeability increases (zonulin >3 ng/mL), allowing LPS into circulation → endotoxemia → systemic inflammation (CRP elevation, insulin resistance)
- Antibiotics reduce bacterial diversity by 30% within 3 days, with incomplete recovery even after 6 months; broad-spectrum antibiotics (fluoroquinolones, clindamycin) cause most severe dysbiosis
- Commensal bacteria produce bacteriocins (antimicrobial peptides) that suppress pathogens; loss of commensals removes competitive inhibition, allowing Candida and pathogenic bacteria to overgrow
¶ Connections
- gut microbiome — bacteria comprise 99% of the microbial biomass in the intestinal ecosystem, outnumbering archaea, viruses, and fungi combined
- LPS — lipopolysaccharide from Gram-negative bacterial outer membranes is the primary endotoxin driving TLR4-mediated systemic inflammation when barrier function fails
- PAMPs — bacterial molecular patterns (LPS, peptidoglycan, flagellin, CpG DNA) are the archetypal pathogen-associated molecular patterns recognized by innate immune PRRs
- TLRs — Toll-like receptors are the first line of bacterial detection, with TLR4 (Gram-negative LPS), TLR2 (Gram-positive peptidoglycan), TLR5 (flagellin), and TLR9 (unmethylated bacterial DNA)
- SCFA — short-chain fatty acids (butyrate, propionate, acetate) are bacterial fermentation products from dietary fiber that serve as colonocyte fuel, HDAC inhibitors, and GPR41/43/109A ligands inducing immune tolerance
- dysbiosis — bacterial imbalance characterized by reduced diversity, loss of SCFA producers, pathogen overgrowth, and functional shifts from symbiosis to dysmetabolism
- antibiotics — antibiotics indiscriminately kill bacteria, depleting beneficial species (Bifidobacteria, Lactobacilli) faster than pathogens, causing dysbiosis, vitamin deficiency (B-complex, K2), and Candida overgrowth
- gut barrier — bacteria regulate tight junction proteins (ZO-1, occludin) and mucus production; commensal bacteria strengthen barriers via butyrate and TLR2 signaling, while pathogens disrupt via zonulin and proteases
- endotoxemia — bacterial translocation across compromised gut barrier releases LPS into portal and systemic circulation, causing metabolic endotoxemia (LPS 5-50 pg/mL) that drives insulin resistance and chronic inflammation
- innate immunity — bacteria are the primary activators of innate immune cells through PRR engagement, determining whether immune response is tolerogenic (IL-10, Tregs) or inflammatory (IL-6, TNF-α)
- Th1 cells — intracellular bacteria (Mycobacterium, Listeria) and bacterial DNA drive Th1 differentiation via IL-12 from dendritic cells for cell-mediated immunity
- Th2 cells — extracellular bacteria and helminth-induced changes in microbiota drive Th2 responses via IL-4, creating protection against parasites but susceptibility to allergy when dysbiotic
- immune tolerance — commensal bacteria induce regulatory T cells via IL-10 and TGF-β, with specific species like Bacteroides fragilis producing PSA that directly drives Foxp3+ Treg differentiation in GALT
- inflammation — pathogenic bacterial overgrowth and loss of SCFA producers creates chronic low-grade inflammation through continuous TLR4 activation and reduced IL-10, underlying metabolic syndrome and neuroinflammation
- B-complex — gut bacteria synthesize thiamine (B1), riboflavin (B2), niacin (B3), pantothenic acid (B5), biotin (B7), folate (B9), and cobalamin (B12); antibiotic-induced dysbiosis necessitates supplementation
- vitamin K2 — menaquinones (MK-4 through MK-13) are synthesized by Bacteroides, Bacillus subtilis, and E. coli, providing 50% of vitamin K2 needs for bone and cardiovascular health
- secondary bile acids — bacteria perform 7α-dehydroxylation of primary bile acids (chenodeoxycholic acid, cholic acid) into secondary bile acids (deoxycholic acid, lithocholic acid) that regulate glucose/lipid metabolism via FXR and TGR5
- indoles — tryptophan-metabolizing bacteria (Clostridium, Lactobacillus) produce indole-3-propionic acid, indole-3-aldehyde, and indole-3-acetic acid that activate AhR (aryl hydrocarbon receptor) for barrier integrity and immune regulation
- Candida — fungal overgrowth occurs when antibiotic-induced bacterial depletion removes competitive inhibition, allowing Candida to expand from <0.1% to >5% of gut microbiota, producing gliotoxin that suppresses remaining bacteria
- secretory IgA — commensal bacteria stimulate B cell IgA class switching in Peyer's patches via TLR activation and APRIL/BAFF cytokines, providing non-inflammatory mucosal defense that coats bacteria without activating complement
- Bifidobacterium — dominant bacterial genus in breastfed infant microbiome (90% of total bacteria), synthesizing B vitamins and producing acetate that lowers gut pH to inhibit pathogens; reduced to <5% in Western adults with dysbiosis
- Lactobacillus — lactic acid-producing bacteria that lower gut pH, synthesize bacteriocins, and produce D-lactate; species like L. rhamnosus GG induce IL-10 and strengthen tight junctions via ZO-1 upregulation
- Faecalibacterium prausnitzii — keystone butyrate-producing species comprising 5-15% of healthy microbiota; reduced to % in IBD, obesity, diabetes; butyrate production requires oxygen-free environment and fiber substrate
- Akkermansia-muciniphila — mucin-degrading bacterium (2-4% of healthy microbiota) that maintains mucus layer homeostasis; pasteurized form increases GLP-1 secretion and improves insulin sensitivity in metabolic syndrome
- Enterobacteriaceae — Gram-negative family (E. coli, Klebsiella, Enterobacter) comprising <1% of healthy microbiota but expanding to >10% in dysbiosis; LPS-rich, facultative anaerobes that thrive in inflamed, oxygen-exposed gut environments
- NF-κB — master transcription factor activated downstream of bacterial TLR signaling, inducing pro-inflammatory cytokine genes (IL1B, IL6, TNF); chronically elevated in dysbiosis-driven metaflammation
- IL-10 — anti-inflammatory cytokine induced by commensal bacteria (especially Bacteroides fragilis PSA) that suppresses NF-κB, promotes Treg differentiation, and maintains immune tolerance; reduced in dysbiosis
- butyrate — 4-carbon SCFA produced by bacterial fiber fermentation, serving as primary colonocyte energy source (β-oxidation), HDAC inhibitor (histone acetylation → Foxp3 expression), and GPR109A ligand (Treg induction)
- zonulin — tight junction modulator released by enterocytes in response to pathogenic bacteria (gliadin, LPS); opens tight junctions by disassembling ZO-1/occludin, increasing permeability; levels >3 ng/mL indicate barrier dysfunction
¶ Module References
- Module 2 — Bacteria as the dominant kingdom in gut microbiome ecology
- Module 4 — Bacterial PAMPs and innate immune system activation
- Module 5 — Dysbiosis and chronic low-grade inflammation pathophysiology